Aleph-6

Aleph-6
Clinical data
Other namesALEPH-6; DOT-6; 4-Phenylthio-2,5-dimethoxyamphetamine; 2,5-Dimethoxy-4-phenylthioamphetamine; 4-PhS-DMA
Routes of
administration
Oral
Drug classSerotonergic psychedelic; Hallucinogen
ATC code
  • None
Pharmacokinetic data
Duration of action"Probably long" (at least 12 hours)
Identifiers
  • 1-(2,5-dimethoxy-4-phenylsulfanylphenyl)propan-2-amine
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC17H21NO2S
Molar mass303.42 g·mol−1
3D model (JSmol)
  • CC(CC1=CC(=C(C=C1OC)SC2=CC=CC=C2)OC)N
  • InChI=1S/C17H21NO2S/c1-12(18)9-13-10-16(20-3)17(11-15(13)19-2)21-14-7-5-4-6-8-14/h4-8,10-12H,9,18H2,1-3H3
  • Key:CSOTVYXYZSJOFL-UHFFFAOYSA-N

Aleph-6, or ALEPH-6, also known as 4-phenylthio-2,5-dimethoxyamphetamine, is a psychedelic drug of the phenethylamine, amphetamine, and DOx families. It is one of the Aleph series of compounds.

In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin lists Aleph-6's dose as greater than 40 mg orally and its duration as "probably long". The effects of Aleph-6 have been reported to include "un-worldliness", among others. It was reported to have synergized with LSD when taken in combination with it. Overall however, Shulgin regarded Aleph-6 as a "disappointment" and that it may be a "forever threshold thing".

The chemical synthesis of Aleph-6 has been described. The 2C analogue, 2C-T-6, has never been synthesized.

Aleph-6 was first described in the literature by Shulgin in PiHKAL in 1991. It is a controlled substance in Canada under phenethylamine blanket-ban language.

See also